Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States.

ABSTRACT:

Introduction

To compare the mortality of hospitalized patients with COVID-19 between those that required supplemental oxygen and received dexamethasone with a comparable set of patients who did not receive dexamethasone.

Methods

We utilized the Premier Health Database to identify hospitalized adult patients with COVID-19 from July 1, 2020-January 31, 2021. Index date was when patients first initiated oxygen therapy. The primary endpoint was in-hospital mortality for patients receiving dexamethasone versus those not receiving dexamethasone 1-day pre- to 1-day post-index period. Secondary endpoints included 28-day mortality, time to in-hospital mortality, progression to invasive mechanical ventilation or death, time to discharge, and proportion discharged alive by day 28. Twen

SUBMITTER: Choong CK 

PROVIDER: S-EPMC9374287 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature